DaVita (NYSE:DVA) updated its FY 2021 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 8.200-9.000 for the period, compared to the Thomson Reuters consensus estimate of $8.250. The company issued revenue guidance of -.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of DaVita from a strong sell rating to a hold rating and set a $117.00 price objective for the company in a research report on Tuesday, February 16th. Bank of America restated an underperform rating and set a $118.00 price objective (down previously from $127.00) on shares of DaVita in a research report on Thursday, April 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. DaVita presently has a consensus rating of Hold and a consensus target price of $123.00.
DVA stock traded down $0.53 during mid-day trading on Friday, reaching $125.41. 302,454 shares of the stock traded hands, compared to its average volume of 751,325. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 4.49. DaVita has a 52-week low of $75.30 and a 52-week high of $129.59. The company has a market cap of $13.32 billion, a P/E ratio of 18.80, a P/E/G ratio of 0.80 and a beta of 1.30. The stock’s fifty day moving average is $113.62 and its 200-day moving average is $110.68.
In other news, Director Pamela M. Arway sold 436 shares of the stock in a transaction that occurred on Monday, March 22nd. The shares were sold at an average price of $109.51, for a total value of $47,746.36. Following the completion of the sale, the director now directly owns 19,239 shares of the company’s stock, valued at $2,106,862.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kathleen Alyce Waters sold 5,290 shares of the stock in a transaction that occurred on Monday, May 3rd. The stock was sold at an average price of $118.36, for a total transaction of $626,124.40. Following the completion of the sale, the insider now directly owns 97,694 shares of the company’s stock, valued at $11,563,061.84. The disclosure for this sale can be found here. Insiders sold 34,651 shares of company stock valued at $4,209,646 over the last three months. 1.00% of the stock is owned by insiders.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Story: Accumulation/Distribution
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.